TWELVE WOMEN WITH PREVIOUSLY IRRADIATED ADVANCED PELVIC CANCER were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase I study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/ M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.
From the University of Alabama at Birmingham.